Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Autolus Therapeutics plcNASDAQ: AUTL
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow dips below year-ago levels
Q1 FY2026 free cash flow of $68M (cash outflow) fell 18.9% year over year, behind the +2.7% change in trailing-twelve-month free cash flow. Sequentially, it fell 25.3% from the prior quarter. Over 3 fiscal years it compounded at +36.1% a year.
Context
- Free cash flow amounted to 411.2% of revenue in FY2025, down 1971.1 pp from a year earlier.
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -18.9% toward the trailing-twelve-month pace of +2.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (310.7M) USD
- Year-over-year change
- -28.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (310.7M) | -28.9% |
| FY2024 | 2024-12-31 | (241.09M) | -54.0% |
| FY2023 | 2023-12-31 | (156.57M) | -27.1% |
| FY2022 | 2022-12-31 | (123.15M) | +2.8% |
| FY2021 | 2021-12-31 | (126.72M) | — |
Free Cash Flow vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 free cash flow of $291.52M is the 2nd largest of the 10 companies compared; the peer median is $101.64M.
- Its year-over-year change of +2.7% is the 2nd highest of 10, against a peer median of -23.5%.
- Free cash flow amounts to 314.9% of revenue for AUTL, versus a peer median of 130.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $320.88M | +70.1% | -9.1% | 23.6% | |
| LTM Mar 2026 | $291.52M | +2.7% | +36.1% | 314.9% | |
| LTM Mar 2026 | $134.42M | -23.5% | -8.0% | 433609.7% | |
| LTM Mar 2026 | $109.53M | -44.7% | -12.8% | — | |
| LTM Mar 2026 | $108.09M | -13.6% | -26.6% | 1711.4% | |
| LTM Mar 2026 | $101.64M | -28.6% | +4.9% | 907.3% | |
| LTM Mar 2026 | $95.91M | -16.0% | +85.0% | — | |
| LTM Mar 2026 | $58.78M | -0.4% | +10.3% | 130.4% | |
| LTM Mar 2026 | $40.14M | -259.5% | -22.1% | 59.0% | |
| LTM Mar 2026 | $25.88M | -61.6% | -43.0% | 111.8% | |
| Peer median (excluding AUTL) | $101.64M | -23.5% | -9.1% | 130.4% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (287.53M) |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.81M |
| Deferred Income Tax | (72K) | (268K) | (986K) | (185K) | (286K) |
| Stock-Based Compensation | 9.94M | 12.01M | 11.2M | 15.47M | 14.44M |
| Change in Working Capital | 4.14M | 3.97M | 292K | (23.66M) | (52.11M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (24.21M) |
| Inventory | 0 | 0 | 0 | (4.23M) | (40.34M) |
| Accounts Payables | (1.82M) | 22K | (509K) | 1.59M | 1.3M |
| Other Working Capital | 5.95M | 3.95M | 801K | (21.02M) | 11.14M |
| Other Non-Cash Items | 1.77M | 13.4M | 45.72M | 15.04M | 32.1M |
| Operating Cash Flow | (117.86M) | (112.31M) | (145.59M) | (206.27M) | (283.57M) |
| Capital Expenditures | (8.86M) | (10.84M) | (10.99M) | (34.82M) | (27.13M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (359.73M) | (242.62M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 428.21M |
| Other Investing Activities | 0 | 0 | 0 | (12.74M) | (8.09M) |
| Investing Cash Flow | (8.86M) | (10.84M) | (10.99M) | (394.55M) | 158.46M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 245.9M | 163.85M | 0 | 549.98M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 38.16M | 59.76M | (883K) | 39.58M | (4.34M) |
| Financing Cash Flow | 284.06M | 223.61M | (883K) | 589.55M | (4.34M) |
| Effect of Forex Changes | (754K) | (28.38M) | 15.03M | (261K) | 6.28M |
| Net Change in Cash | 156.59M | 72.09M | (142.43M) | (11.53M) | (123.17M) |
| Free Cash Flow | (126.72M) | (123.15M) | (156.57M) | (241.09M) | (310.7M) |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.